Cam2020 M2SR H3N2 monovalent influenza vaccine / FluGen - LARVOL DELTA

Safety and Immunogenicity of Cam2020 M2SR H3N2 Monovalent Influenza Vaccine Alone or With Licensed IIV in Older Adults (clinicaltrials.gov) - P1b | N=303 | Completed | Sponsor: FluGen Inc | Active, not recruiting ➔ Completed | Trial completion date: Mar 2023 ➔ Nov 2022

Trial completion • Trial completion date • Infectious Disease • Influenza • Respiratory Diseases

Safety and Immunogenicity of Cam2020 M2SR H3N2 Monovalent Influenza Vaccine Alone or With Licensed IIV in Older Adults (clinicaltrials.gov) - P1b | N=300 | Active, not recruiting | Sponsor: FluGen Inc | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Influenza • Respiratory Diseases

Safety and Immunogenicity of Cam2020 M2SR H3N2 Monovalent Influenza Vaccine Alone or With Licensed IIV in Older Adults (clinicaltrials.gov) - P1b | N=300 | Recruiting | Sponsor: FluGen Inc | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Respiratory Diseases